Clinical Trial

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Name: Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma — clinical trial record (NCT06190067)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2023-12-19.

Trial Details

NCT Number	NCT06190067
Lead Sponsor	Navy General Hospital, Beijing
Conditions	Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Enrollment	40 participants
Start Date	2023-10-30
Primary Completion	2026-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2024-01-30